Shares of Tempus AI (TEM), a leading technology company in precision medicine and AI-driven patient care, surged 7.92% in the pre-market session on Wednesday. This significant rally was driven by the company's announcement of the national launch of its FDA-approved xT CDx test for comprehensive solid tumor profiling.

xT CDx is a 648-gene next-generation sequencing (NGS) test that can detect various genetic alterations in solid tumors, including single nucleotide variants, multi-nucleotide variants, insertions, deletions, and microsatellite instability status. The test leverages a normal-matched approach, which involves parallel DNA sequencing of tumor and normal patient samples, potentially leading to more accurate identification of cancer-driving somatic variants.

The FDA approval and nationwide availability of xT CDx mark a significant milestone for Tempus AI, as it expands access to its trusted and comprehensive genomic profiling solution for cancer patients across the United States. With its extensive gene panel and companion diagnostic claims, xT CDx can provide clinicians with actionable insights to guide targeted therapy selection and improve patient outcomes in the field of precision oncology.